Stay updated with breaking news from Albert Mitrani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Organicell’s Zofin™ therapy has been approved by Pakistani regulators to be used for a patient with severe COVID-19 on compassionate grounds.
The first ten patients in a Phase I trial of Zofin™ have recovered, the trial will now expand with an additional 65 participants.
Organicell concludes patient enrolment for expanded Covid-19 trial 23 Apr 2021 (Last Updated April 23rd, 2021 17:25) Organicell Regenerative Medicine has concluded patient enrolment for its expanded access trial for investigational product Zofin to treat Covid-19. Share Article Organicell is evaluating intravenous infusion of Zofin in a Phase I/II randomised Covid-19 trial. Credit: LuAnn Hunt from Pixabay. Organicell Regenerative Medicine has concluded patient enrolment for its expanded access trial for investigational product Zofin to treat Cov...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “ Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Act of 1934, as amended (the “ Exchange Act”). Upon filing is Quarterly Report on Form 10-Q for the Quarter ended July 31, 2020 on December 18, 2020, the Company became current in its SEC reporting requirements under the Exchange Act. The Company had not been current in such filings since the filing of its Quarterly Report...